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Past
events
Current status of the field
Nuclear medicine and positron emission tomography (PET) 
continues to be on the forefront of molecular imaging. In the past 
decade, PET imaging established itself as the gold standard for 
cancer staging and therapy follow up. To lesser extent, PET is also 
used clinically in cardiology (myocardial perfusion) and neurology 
(dementia). The wide adoption of oncology applications of FDG 
PET imaging drove technology development towards (1) improve-
ments in image quality and (2) integration with anatomical imaging. 
PET image quality improvements were achieved by novel detector 
design, commercialization of the time of flight PET & advances in 
patient motion management. Today, almost all new PET systems are 
integrated with diagnostic CT scanners. Combination of anatomical 
detail provided by CT with metabolic / molecular information from 
PET improved diagnostic accuracy and proved the usefulness of 
multimodality imaging in a routine clinical setting. 
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Future directions for the field
PET imaging is already undergoing a significant change 
— a shift from disease detection towards disease characteriza-
tion. From imaging technology perspective, it means a move 
towards quantitative imaging. Quantitative PET imaging means reli-
able, consistent system performance, accurate absolute measure-
ment of activity concentration and parametric imaging of specific 
biomarkers (dynamic imaging & pharmacokinetics). There is also 
growing consensus that a composite picture of several biomark-
ers will be necessary to characterize the disease. Integration of PET 
& MR imaging could enable such characterization by leveraging 
molecular imaging potential of both modalities. These technical 
developments combined with the development of novel radiophar-
maceuticals could enable the use of PET imaging for planning and 
monitoring of individualized targeted therapies fulfilling a dream 
of molecular medicine.
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